ICYMI: Drug that May Slow Parkinson's Advancing to Phase III

Dear Friend,

Earlier this month, we shared news of a  Phase III trial of inosine, a potential disease-modifying treatment for Parkinson's disease (PD), based on findings from research funded by The Michael J. Fox Foundation.

This has been followed by two new developments with promise to improve the lives of those living with PD:

• Researchers used data from the MJFF-sponsored Parkinson's Progression Markers Initiative to set five criteria for differentiating people with PD  that can possibly predict who will get Parkinson's disease.
  
• Acadia Pharmaceuticals announced that it is seeking FDA approval of its drug Nuplazid for the treatment of psychosis associated with PD.

Help us drive the momentum we see in the field even further. Donate today to support Parkinson's research that will help speed a cure. 

Thank you, 

Todd ShererCEO 

Another Drug that May Slow Parkinson's Advancing to Phase III Trial After Early MJFF Support
	Recruitment for the inosine study will begin early next year.
	Today researchers testing the compound inosine for its effect on Parkinson's progression announced funding from the National Institutes of Health for a Phase III trial, the last step before regulatory approval. The Michael J. Fox Foundation provided essential support for early laboratory testing and the Phase II safety trial and will fund two small, required follow-up safety studies.The contributions of MJFF donors like you made this study possible. Continue to support promising Parkinson's research by making a donation today. Learn more about the inosine study.
	Support Research >